Funding sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Conflicts of interest The authors KE Broekman, M Jalving, H van Tinteren, C Sessa and AKL Reyners declare that they have no competing interests. Appendi...
Y.-L.W. reports getting honoraria from AstraZeneca, Lily, Roche, Pfizer, Boehringer Ingelheim, MSD Oncology, Bristol-Myers Squibb/China, Hengrui Pharmaceutical and BeiGene Beijing; consulting and advisory services for AstraZeneca, Roche and Takeda; and getting research funding from Roche, Boehringer...
significantly higher than that in the FOLFIRI group [81], which aligns with the results of this study. Furthermore, three RCTs [26,30,40] also indicated that FOLFOXIRI + bevacizumab might increase the risk of grade 3 or higher AEs when directly compared with FOLFOX/FOLFIRI + bevaci...
Funding This work was supported by the National Natural Science Foundation of China and (Nos. 92059207) and the Office of Science and Technology and Talent Work of Luzhou (Nos. 2023JYJ063). Author information Author notes Gang Zhu and Longfei Zeng contributed equally to this work. Authors and...
Funding The research was supported by the Scientific Grant Agency of the Ministry of Education of Slovak Republic and the Slovak Academy of Sciences VEGA (Project No. 1/0017/20) (Changes in the Application of Managerial Functions in the Context of the Fourth Industrial Revolution and Adaptation ...
Unless future studies identify potentially useful predictive biomarkers, necitumumab is unlikely to provide benefit in this patient population when combined with pemetrexed and cisplatin. Funding Eli Lilly and Company. 展开 DOI: 10.1016/S1470-2045(15)70046-X 被引量: 121 年份: 2015 ...
Funding GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania (no grant number applies). MF is supported by NHMRC Program Grant 1092856 “Improving outcomes for women with ovarian cancer”. NHMRC 1092856 Disclosure MF received honoraria for advisory boards from AstraZeneca and Pfizer as well as res...
(FACT-G and FKSI). D.C. has received consulting honoraria from Bristol-Myers Squibb, Ipsen, Pfizer, Merck and Novartis, and has received research funding to his institution from Bristol-Myers Squibb, Pfizer and Merck; these companies sponsored or collaborated on the following clinical trials ...
Funding The authors initially developed a framework and concept for this manuscript, and then sought editorial support to facilitate and expedite completion. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, supported this independent editorial support to the aut...
Funding Eli Lilly. Introduction Colorectal carcinoma is the third most common cancer worldwide. Around 1·4 million cases are diagnosed each year; 746 000 in men (third most common for men) and 614 000 in women (second most common for women).150% of all patients with colorectal carcino...